Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai's Perampanel Phase III Outcomes Show Efficacy, But May Not Meet Company Hype

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai Co. Ltd. released generally positive results of a Phase III trial for epilepsy drug perampanel, a compound which the company has promoted heavily to investors and analysts, but discouraging results on dose-dependent efficacy may contribute to an underperformance of the hyped drug, according to a Tokyo pharma analyst
Advertisement

Related Content

With New Mechanism, Can Eisai’s Fycompa Make Its Mark In Epilepsy?
Eisai Wins FDA Approval For Novel, Once-Daily Seizure Drug Fycompa
Post-Aricept Patent Expiry, Eisai Starts Comeback With Roll-Out Of New Anti-Epileptic Fycompa In Europe
Japan Earnings Roundup: Astellas' Oncology Gains, Eisai Hit Hard, KHK Domestic Strength
China's Simcere Beats Out Eisai In Iguratimod Approval For Rheumatoid Arthritis
Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China
Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines
Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines
Advertisement
UsernamePublicRestriction

Register

SC078895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel